A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
{{output}}
Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castration-resistant prosta... ...
